Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 26, 2009 Rich Smith	This Just In: Upgrades and Downgrades Alphabet love: RBC picks HP to outperform.
The Motley Fool October 1, 2010 Rich Smith	This Just In: Upgrades and Downgrades RBC Capital named Best Buy its literal "top pick" in the specialty retail sector.
The Motley Fool November 19, 2009 Rich Smith	This Just In: Upgrades and Downgrades On a market-dropping day, thanks to an upgrade from RBC Capital, thin-film solar specialist First Solar not only sidestepped the carnage, but actually rose higher.
The Motley Fool September 30, 2008 Rich Smith	This Just In: Upgrades and Downgrades Apple bruised by twin downgrades.
The Motley Fool February 27, 2009 Rich Smith	This Just In: Upgrades and Downgrades Canadian investment banker RBC Capital Markets weighs in on telephone companies, upgrading Verizon to "outperform."
The Motley Fool August 12, 2010 Jordan DiPietro	7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels.
The Motley Fool July 23, 2010 Jordan DiPietro	Better Health Care Buy: Stryker or Zimmer Holdings? Which stock is a better purchase to consider?
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool February 24, 2010 Rich Smith	This Just In: Upgrades and Downgrades Horrified at the company's performance in the 2010 fiscal first quarter, each of UBS, Jefferies, Stifel Nicolaus, and RBC Capital Markets pulled their "buy" ratings, and downgraded the stock to various flavors of "hold."
The Motley Fool April 6, 2009	3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Baxter International... Abbott Laboratories...
The Motley Fool September 2, 2010 Jordan DiPietro	5 Big-Time Health Service Stocks Up For Grabs These large-cap health-care service stocks look pretty cheap: Stryker... Medtronic... Covidien... WellPoint, Inc... St. Jude Medical...
The Motley Fool September 5, 2008 Brian Orelli	Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business.
The Motley Fool December 22, 2009	9 Cheap Stocks Our Experts Adore Are they right for you? Maybe we've found a few stocks for all you bargain hunters out there.
The Motley Fool March 17, 2009	2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce?
The Motley Fool February 6, 2009	2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Evergreen Solar... Team, Inc. ...
The Motley Fool November 23, 2009	Casual Male Retail Group, Inc.: Warming Up or Cooling Off? What we think about the direction of this company's stock.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
The Motley Fool July 28, 2010 Brian Orelli	Amplifying the Risk-Reward Ratio Amplify, Medtronic's latest, gets a mixed reaction at FDA advisory panel meeting.
The Motley Fool January 31, 2006 Stephen D. Simpson	Zimmer Muddles Through So long as the pressures in the orthopedic sector prove less than originally feared, investors could still make money here.
The Motley Fool April 17, 2008 Brian Orelli	Abbott's Not Ailing Abbott produces double-digit growth; investors yawn.
The Motley Fool October 16, 2009 Robert Steyer	Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution.
The Motley Fool July 13, 2011 Zeeshan Siddique	Can You Bank on Royal Bank of Canada? In context with its growth prospects, RBC's pricing looks a bit stretched.
The Motley Fool April 15, 2009 Brian Orelli	Abbott's on Sale Abbott isn't firing on all cylinders the way it was last year, but things still look fine, and the stock is selling at a discount right now.
The Motley Fool January 25, 2006 Stephen D. Simpson	Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
The Motley Fool July 7, 2008 Brian Orelli	And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V.
The Motley Fool October 21, 2010 Brian Orelli	Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool June 1, 2011 Zeeshan Siddique	Royal Bank of Canada Fails to Match Up to Investors' Expectations Despite posting profits, RBC's shares fell by 3%.
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool April 22, 2010 Brian Orelli	Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care.
The Motley Fool January 20, 2012 Jacob Roche	This Hidden Gem Is Poised to Profit Dorman Products will benefit from a long-term trend.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool April 11, 2011 Zeeshan Siddique	Here's Why RBC Shouldn't Sell Its Retail U.S. Business Now Royal Bank of Canada shouldn't sell off its U.S retail unit as it may improve with the recovering economy.
On Wall Street March 1, 2012	Letter to the Editor Letter to the Editor: Recruiter Roundtable: Defending RBC...
The Motley Fool July 23, 2009 Robert Steyer	Long Convalescence for Device Makers Orthopedic product specialists Stryker and Zimmer Holdings forecast a slow-motion recovery.
The Motley Fool April 28, 2004 Glen Trematore	Zimmer Makes a Family Proud Zimmer Holdings looks strong when compared with other orthopedic/medical device makers.
The Motley Fool September 23, 2010 Brian Orelli	This Recall Should Bug You Abbott Labs announces a recall of some types of its Similac baby formula because it found beetles and their larvae in an area of one of its plants.
The Motley Fool January 30, 2009 Brian Orelli	Good Luck in 2010, Zimmer Medical device maker Zimmer met analysts expectations in the fourth quarter, but investors weren't impressed with the company's guidance.
The Motley Fool May 27, 2011 Andrew Tonner	Does Zimmer Holdings Deserve a Spot in Your Portfolio? Compared to it's peers, Zimmer Holdings doesn't look like a stock for your portfolio right now.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool April 1, 2011 Brian Orelli	Abbott: Battle Lost, War Won A jury ordered Abbott to pay GlaxoSmithKline $3.5 million. It could have been a lot worse.
The Motley Fool March 3, 2009	3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Genesee & Wyoming, Inc. ... Jinpan International Limited... Columbia Sportswear Company...
The Motley Fool January 29, 2007 Matthew Crews	Only One Bone to Pick With Stryker With products for wherever you hurt, the med-tech company continues to deliver solid earnings.
The Motley Fool August 26, 2008 Brian Orelli	Rapid Exchange of Fire Competitors try to block Abbott's patent extension.